DesignMedix, Inc develops drugs to overcome drug resistance in multiple diseases, and has a malaria drug ready for human trials, to be sponsored by the NIH.
DesignMedix develops impactful disease cures that overcome drug resistance, a major threat to human health. Leveraging $3M in angel investment with over $12M in non-dilutive funding, DesignMedix has efficiently used angel investment to develop a novel malaria cure, ready for human safety trials to be sponsored by the NIH. Immediately upon FDA approval, the drug will be eligible for a tradable Priority Review Voucher. Recent PRV sales: $125-350M.